CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.1.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Market share analysis, 2018
3.4.Porter's five forces analysis
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in consumption in low-and middle-income countries (LMICs)
3.5.1.2.Rise in prevalence of infectious diseases
3.5.1.3.Development of novel approaches

3.5.2.Restraints

3.5.2.1.Development of antibiotic resistance
3.5.2.2.Time consuming approvals

3.5.3.Opportunities

3.5.3.1.Discovery of advanced therapies to treat antibiotic-resistance.

3.6.Impact analysis of COVID-19 on oral antibiotics market

CHAPTER 4:ORAL ANTIBIOTICS MARKET, BY CLASS

4.1.Overview

4.1.1.Market size and forecast, by class

4.2.Beta lactam and beta lactamase inhibitors

4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast, by type

4.2.2.1.Penicillin

4.2.2.1.1.Market size and forecast, by type

4.2.2.1.1.1.Broad-spectrum penicillin
4.2.2.1.1.2.Mid/Narrow-spectrum penicillin

4.2.2.2.Cephalosporin

4.2.2.2.1.Market size and forecast
4.2.2.2.2.Market size and forecast, by molecule

4.2.2.3.Others

4.2.2.3.1.Market size and forecast

4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country

4.3.Quinolones

4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Macrolides

4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Others

4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

CHAPTER 5:ORAL ANTIBIOTICS MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Community-acquired respiratory tract infections (CARTIs)

5.2.1.Market size and forecast, by type

5.2.1.1.Upper Respiratory Tract Infections (URTI)

5.2.1.1.1.Market size and forecast
5.2.1.1.2.Market size and forecast, by molecule

5.2.1.2.Lower Respiratory Tract Infections (LRTIs)

5.2.1.2.1.Market size and forecast
5.2.1.2.2.Market size and forecast, by molecule

5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country

5.3.Urinary tract infections (UTIs)

5.3.1.Market size and forecast, by molecule
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country

5.4.Dental

5.4.1.Market size and forecast, by type

5.4.1.1.Combination

5.4.1.1.1.Market size and forecast
5.4.1.1.2.Market size and forecast, by molecule

5.4.1.2.Monotherapies

5.4.1.2.1.Market size and forecast
5.4.1.2.2.Market size and forecast, by molecule

5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country

5.5.Others

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

CHAPTER 6:ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN

6.1.Overview

6.1.1.Market size and forecast

6.2.Natural

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Semisynthetic

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Synthetic

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY

7.1.Overview

7.1.1.Market size and forecast

7.2.Broad-spectrum antibiotic

7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country

7.3.Mid/Narrow-spectrum antibiotic

7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country

CHAPTER 8:ORAL ANTIBIOTICS MARKET, BY DRUG TYPE

8.1.Overview

8.1.1.Market size and forecast

8.2.Branded

8.2.1.Market size and forecast, by region
8.2.2.Market analysis, by country

8.3.Generics

8.3.1.Market size and forecast, by region
8.3.2.Market analysis, by country

CHAPTER 9:ORAL ANTIBIOTICS MARKET, BY REGION

9.1.Overview

9.1.1.Market size and forecast

9.2.North America

9.2.1.Key market trends and opportunities
9.2.2.North America antibiotics market, by country

9.2.2.1.U.S. oral antibiotics market, by class
9.2.2.2.U.S. oral antibiotics market, by application
9.2.2.3.U.S. oral antibiotics market, by drug origin
9.2.2.4.U.S. oral antibiotics market, by spectrum of activity
9.2.2.5.U.S. oral antibiotics market, by Drug type
9.2.2.6.Canada oral antibiotics market, by class
9.2.2.7.Canada oral antibiotics market, by application
9.2.2.8.Canada oral antibiotics market, by drug origin
9.2.2.9.Canada oral antibiotics market, by spectrum of activity
9.2.2.10.Canada oral antibiotics market, by drug type
9.2.2.11.Mexico oral antibiotics market, by class162
9.2.2.12.Mexico oral antibiotics market, by application
9.2.2.13.Mexico oral antibiotics market, by drug origin
9.2.2.14.Mexico oral antibiotics market, by spectrum of activity
9.2.2.15.Mexico oral antibiotics market, by drug type

9.2.3.North America oral antibiotics market, by class
9.2.4.North America oral antibiotics market, by application
9.2.5.North America oral antibiotics market, by drug origin
9.2.6.North America oral antibiotics market, by spectrum of activity
9.2.7.North America antibiotics market, by drug type

9.3.Europe

9.3.1.Key market trends and opportunities
9.3.2.Europe oral antibiotics market, by country

9.3.2.1.Germany oral antibiotics market, by class
9.3.2.2.Germany oral antibiotics market, by application
9.3.2.3.Germany oral antibiotics market, by drug origin
9.3.2.4.Germany oral antibiotics market, by spectrum of activity
9.3.2.5.Germany oral antibiotics market, by Drug type
9.3.2.6.France oral antibiotics market, by class
9.3.2.7.France oral antibiotics market, by application
9.3.2.8.France oral antibiotics market, by drug origin
9.3.2.9.France oral antibiotics market, by spectrum of activity
9.3.2.10.France oral antibiotics market, by drug type
9.3.2.11.Spain oral antibiotics market, by class181
9.3.2.12.Spain oral antibiotics market, by application
9.3.2.13.Spain oral antibiotics market, by drug origin
9.3.2.14.Spain oral antibiotics market, by spectrum of activity
9.3.2.15.Spain oral antibiotics market, by drug type
9.3.2.16.Italy oral antibiotics market, by class185
9.3.2.17.Italy oral antibiotics market, by application
9.3.2.18.Italy oral antibiotics market, by drug origin
9.3.2.19.Italy oral antibiotics market, by spectrum of activity
9.3.2.20.Italy oral antibiotics market, by drug type
9.3.2.21.UK oral antibiotics market, by class
9.3.2.22.UK oral antibiotics market, by application
9.3.2.23.UK oral antibiotics market, by drug origin
9.3.2.24.UK oral antibiotics market, by spectrum of activity
9.3.2.25.UK oral antibiotics market, by drug type
9.3.2.26.Russia oral antibiotics market, by class
9.3.2.27.Russia oral antibiotics market, by application
9.3.2.28.Russia oral antibiotics market, by drug origin
9.3.2.29.Russia oral antibiotics market, by spectrum of activity
9.3.2.30.Russia oral antibiotics market, by drug type
9.3.2.31.Rest of Europe oral antibiotics market, by class
9.3.2.32.Rest of Europe oral antibiotics market, by application
9.3.2.33.Rest of Europe oral antibiotics market, by drug origin
9.3.2.34.Rest of Europe oral antibiotics market, by spectrum of activity
9.3.2.35.Rest of Europe oral antibiotics market, by drug type

9.3.3.Europe oral antibiotics market, by class
9.3.4.Europe oral antibiotics market, by application
9.3.5.Europe oral antibiotics market, by drug origin
9.3.6.Europe oral antibiotics market, by spectrum of activity
9.3.7.Europe oral antibiotics market, by drug type

9.4.Asia-Pacific

9.4.1.Key market trends and opportunities
9.4.2.Asia-Pacific oral antibiotics market, by country

9.4.2.1.Japan oral antibiotics market, by class
9.4.2.2.Japan oral antibiotics market, by application
9.4.2.3.Japan oral antibiotics market, by drug origin
9.4.2.4.Japan oral antibiotics market, by spectrum of activity
9.4.2.5.Japan oral antibiotics market, by drug type
9.4.2.6.India oral antibiotics market, by class
9.4.2.7.India oral antibiotics market, by application
9.4.2.8.India oral antibiotics market, by drug origin
9.4.2.9.India oral antibiotics market, by spectrum of activity
9.4.2.10.India oral antibiotics market, by drug type
9.4.2.11.China oral antibiotics market, by class
9.4.2.12.China oral antibiotics market, by application
9.4.2.13.China oral antibiotics market, by drug origin
9.4.2.14.China oral antibiotics market, by spectrum of activity
9.4.2.15.China oral antibiotics market, by drug type
9.4.2.16.Pakistan oral antibiotics market, by class
9.4.2.17.Pakistan oral antibiotics market, by application
9.4.2.18.Pakistan oral antibiotics market, by drug origin
9.4.2.19.Pakistan oral antibiotics market, by spectrum of activity
9.4.2.20.Pakistan oral antibiotics market, by Drug type
9.4.2.21.Vietnam oral antibiotics market, by class
9.4.2.22.Vietnam oral antibiotics market, by application
9.4.2.23.Vietnam oral antibiotics market, by drug origin
9.4.2.24.Vietnam oral antibiotics market, by spectrum of activity
9.4.2.25.Vietnam oral antibiotics market, by Drug type
9.4.2.26.Rest of Asia-Pacific oral antibiotics market, by class
9.4.2.27.Rest of Asia-Pacific oral antibiotics market, by application
9.4.2.28.Rest of Asia-Pacific oral antibiotics market, by drug origin
9.4.2.29.Rest of Asia-Pacific oral antibiotics market, by spectrum of activity
9.4.2.30.Rest of Asia-Pacific oral antibiotics market, by drug type

9.4.3.Asia-Pacific oral antibiotics market, by class
9.4.4.Asia-Pacific oral antibiotics market, by application
9.4.5.Asia-Pacific oral antibiotics market, by drug origin
9.4.6.Asia-Pacific oral antibiotics market, by spectrum of activity
9.4.7.Asia-Pacific oral antibiotics market, by drug type

9.5.LAMEA

9.5.1.Key market trends and opportunities
9.5.2.LAMEA antibiotics market, by country

9.5.2.1.Brazil oral antibiotics market, by class
9.5.2.2.Brazil oral antibiotics market, by application
9.5.2.3.Brazil oral antibiotics market, by drug origin
9.5.2.4.Brazil oral antibiotics market, by spectrum of activity
9.5.2.5.Brazil oral antibiotics market, by drug type
9.5.2.6.Saudi Arabia oral antibiotics market, by class
9.5.2.7.Saudi Arabia oral antibiotics market, by application
9.5.2.8.Saudi Arabia oral antibiotics market, by drug origin
9.5.2.9.Saudi Arabia oral antibiotics market, by spectrum of activity
9.5.2.10.Saudi Arabia oral antibiotics market, by application
9.5.2.11.South Africa oral antibiotics market, by class
9.5.2.12.South Africa oral antibiotics market, by application
9.5.2.13.South Africa oral antibiotics market, by drug origin
9.5.2.14.South Africa oral antibiotics market, by spectrum of activity
9.5.2.15.South Africa oral antibiotics market, by drug type
9.5.2.16.Turkey oral antibiotics market, by class
9.5.2.17.Turkey oral antibiotics market, by application
9.5.2.18.Turkey oral antibiotics market, by drug origin
9.5.2.19.Turkey oral antibiotics market, by spectrum of activity
9.5.2.20.Turkey oral antibiotics market, by drug type
9.5.2.21.Rest of LAMEA oral antibiotics market, by class
9.5.2.22.Rest of LAMEA oral antibiotics market, by application
9.5.2.23.Rest of LAMEA oral antibiotics market, by drug origin
9.5.2.24.Rest of LAMEA oral antibiotics market, by spectrum of activity
9.5.2.25.Rest of LAMEA oral antibiotics market, by drug type

9.5.3.LAMEA antibiotics market, by class
9.5.4.LAMEA antibiotics market, by application
9.5.5.LAMEA antibiotics market, by drug origin
9.5.6.LAMEA antibiotics market, by spectrum of activity
9.5.7.LAMEA antibiotics market, by drug type

CHAPTER 10:COMPANY PROFILES

10.1.ABBOTT LABORATORIES

10.1.1.Company overview
10.1.2.Company snapshot
10.1.3.Operating business segments
10.1.4.Product portfolio
10.1.5.Business performance

10.2.ALLERGAN PLC

10.2.1.Company overview
10.2.2.Company snapshot
10.2.3.Operating business segments
10.2.4.Product portfolio
10.2.5.Business performance
10.2.6.Key strategic moves and developments

10.3.F. HOFFMANN-LA ROCHE LTD.

10.3.1.Company overview
10.3.2.Company snapshot
10.3.3.Operating business segments
10.3.4.Product portfolio
10.3.5.Business performance
10.3.6.Key strategic moves and developments

10.4.GLAXOSMITHKLINE PLC

10.4.1.Company overview
10.4.2.Company snapshot
10.4.3.Operating business segments
10.4.4.Product portfolio
10.4.5.Business performance
10.4.6.Key strategic moves and developments

10.5.MERCK & CO., INC.

10.5.1.Company overview
10.5.2.Company snapshot
10.5.3.Operating business segments
10.5.4.Product portfolio
10.5.5.Business performance
10.5.6.Key strategic moves and developments

10.6.MYLAN N.V.

10.6.1.Company overview
10.6.2.Company snapshot
10.6.3.Operating business segments
10.6.4.Product portfolio
10.6.5.Business performance
10.6.6.Key strategic moves and developments

10.7.NOVARTIS INTERNATIONAL AG (PEAR THERAPEUTICS, INC.)

10.7.1.Company overview
10.7.2.Company snapshot
10.7.3.Operating business segments
10.7.4.Product portfolio
10.7.5.Business performance
10.7.6.Key strategic moves and developments

10.8.PFIZER INC.

10.8.1.Company overview
10.8.2.Company snapshot
10.8.3.Operating business segments
10.8.4.Operating Product
10.8.5.Business performance
10.8.6.Key strategic moves and developments

10.9.SANOFI

10.9.1.Company overview
10.9.2.Company snapshot
10.9.3.Operating business segments
10.9.4.Product portfolio
10.9.5.Business performance
10.9.6.Key strategic moves and developments

10.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.

10.10.1.Company overview
10.10.2.Company snapshot
10.10.3.Operating business segments
10.10.4.Product portfolio
10.10.5.Business performance